Skip to main content
MedPathMedPath Home
Clinical Trials/2023-504007-91-00
2023-504007-91-00
Completed
Phase 1

A Phase 1, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics Of Mavodelpar In Subjects With Impaired Hepatic Function

Reneo Pharmaceuticals Inc.1 site in 1 country32 target enrollmentStarted: July 4, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Status
Completed
Sponsor
Reneo Pharmaceuticals Inc.
Enrollment
32
Locations
1
OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Reneo Pharmaceuticals Inc.
Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Willis Chou

Scientific

Reneo Pharmaceuticals Inc.

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
An open-label, single-dose phase 1 study to evaluate the Absorption, Metabolism, and Excretion of [14C]-AZ-3102 in Healthy Male Subjects
2023-504916-14-00Azafaros B.V.7
Recruiting
Phase 1
Study of CM383 in Healthy Subjects
NCT07292688Keymed Biosciences Co.Ltd30
Not yet recruiting
Phase 1
A phase 1, controlled, open-label, single dose, dose-escalation, clinical proof-of-concept study of MRI enhanced with ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in patients with brain amyloid deposits as demonstrated by amyloid PET
2024-520078-36-00Alzeca Biosciences Inc.18
Completed
Phase 1
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
2023-509399-40-00Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A.30
Completed
Phase 1
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 12 mg film-coated tablets versus reference product Fycompa 12 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions.
2023-503345-59-00Laboratorios Cinfa S.A.36